Corrigendum to "The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation" [Free Radic. Biol. Med. 47/4 (2009) 419-423] (DOI:10.1016/j.freeradbiomed.2009.05.011);The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation

Free Radical Biology and Medicine

Volumn 47, Issue 4, 2009, Pages 419-423

  Samuni, Yuval ^a   Flores Santana, Wilmarie ^a   Krishna, Murali C ^a   Mitchell, James B ^a   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EPR; Free radicals; HDAC; NO; Oxidation; SAHA

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROGEN PEROXIDE; METMYOGLOBIN; NITRIC OXIDE; NITRITE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CELL STRAIN V 79; CELL SURVIVAL; CONTROLLED STUDY; DRUG STRUCTURE; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; EPIGENETICS; INCUBATION TIME; MAMMAL CELL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPIN TRAPPING;

CRICETULUS GRISEUS; MAMMALIA;

EID: 67649836821     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.10.001     Document Type: Erratum

References (42)

1. Breslow R., Jursic B., Yan Z.F., Friedman E., Leng L., Ngo L., Rifkind R.A., and Marks P.A. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc. Natl. Acad. Sci. USA 88 (1991) 5542-5546
2. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 5165-5170
3. Mann B.S., Johnson J.R., He K., Sridhara R., Abraham S., Booth B.P., Verbois L., Morse D.E., Jee J.M., Pope S., Harapanhalli R.S., Dagher R., Farrell A., Justice R., and Pazdur R. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13 (2007) 2318-2322
4. Vansteenkiste J., Van Cutsem E., Dumez H., Chen C., Ricker J.L., Randolph S.S., Schoffski P., and Early phase I.I. trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 26 (2008) 483-488
5. Marks P.A., and Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25 (2007) 84-90
6. Kelly W.K., and Marks P.A. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2 (2005) 150-157
7. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific-inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin-A. J. Biol. Chem. 265 (1990) 17174-17179
8. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
9. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 26 (2007) 1351-1356
10. Denicola A., Souza J.M., Gatti R.M., Augusto O., and Radi R. Desferrioxamine inhibition of the hydroxyl radical-like reactivity of peroxynitrite-role of the hydroxamic groups. Free Radic. Biol. Med. 19 (1995) 11-19
11. Marmion C.J., Murphy T., Docherty J.R., and Nolan K.B. Hydroxamic acids are nitric oxide donors: facile formation of ruthenium(II)-nitrosyls and NO-mediated activation of guanylate cyclase by hydroxamic acids. Chem. Commun. (2000) 1153-1154
12. Gladwin M.T., Shelhamer J.H., Ognibene F.P., Pease-Fye M.E., Nichols J.S., Link B., Patel D.B., Jankowski M.A., Pannell L.K., Schechter A.N., and Rodgers G.P. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br. J. Haematol. 116 (2002) 436-444
13. Granik V.G., and Grigor'ev N.A. Exogenous donors of nitric oxide (a chemical aspect). Russ. Chem. Bull. 51 (2002) 1375-1422
14. Stolze K., and Nohl H. EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin. Biochem. Pharmacol. 40 (1990) 799-802
15. Jiang J.J., Jordan S.J., Barr D.P., Gunther M.R., Maeda H., and Mason R.P. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol. Pharmacol. 52 (1997) 1081-1086
16. King S.B. Mechanisms and novel directions in the biological applications of nitric oxide donors. Free Radic. Biol. Med. 37 (2004) 735-736
17. Burkitt M.J., and Raafat A. Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood 107 (2006) 2219-2222
18. 15N]nitrate in biological fluids. Anal. Biochem. 126 (1982) 131-138
19. Huang J.M., Sommers E.M., Kim-Shapiro D.B., and King S.B. Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. J. Am. Chem. Soc. 124 (2002) 3473-3480
20. King S.B. The nitric oxide producing reactions of hydroxyurea. Curr. Med. Chem. 10 (2003) 437-452
21. King S.B. N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr. Top. Med. Chem. 5 (2005) 665-673
22. King N.K., and Winfield M.E. The mechanism of metmyoglobin oxidation. J. Biol. Chem. 238 (1963) 1520-1528
23. Rao S.I., Wilks A., Hamberg M., and Demontellano P.R.O. The lipoxygenase activity of myoglobin-oxidation of linoleic-acid by the ferryl oxygen rather than protein radical. J. Biol. Chem. 269 (1994) 7210-7216
24. Kelman D.J., Degray J.A., and Mason R.P. Reaction of myoglobin with hydrogen-peroxide forms a peroxyl radical which oxidizes substrates. J. Biol. Chem. 269 (1994) 7458-7463
25. Krishna M.C., Samuni A., Taira J., Goldstein S., Mitchell J.B., and Russo A. Stimulation by nitroxides of catalase-like activity of hemeproteins-kinetics and mechanism. J. Biol. Chem. 271 (1996) 26018-26025
26. {radical dot}NO through a radical reaction. Biochemistry 32 (1993) 827-832
27. Akaike T., and Maeda H. Quantitation of nitric oxide using 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO). Nitric Oxide, Pt A, Sources and Detection of NO; NO Synthase (1996), San Diego, Academic Press 211-221
28. Az-ma T., Fujii K., and Yuge O. Reaction between imidazolineoxil N-oxide (carboxy-PTIO) and nitric-oxide released from cultured endothelial-cells-quantitative measurement of nitric-oxide by ESR spectrometry. Life Sci. 54 (1994) PL185-PL190
29. Pacelli R., Taira J., Cook J.A., Wink D.A., and Krishna M.C. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 347 (1996) 900
30. Taira J., Misik V., and Riesz P. Nitric oxide formation from hydroxylamine by myoglobin and hydrogen peroxide. Biochim. Biophys. Acta Gen. Subj. 1336 (1997) 502-508
31. Manning P., Cookson M.R., McNeil C.J., Figlewicz D., and Shaw P.J. Superoxide-induced nitric oxide release from cultured glial cells. Brain Res. 911 (2001) 203-210
32. Bobko A.A., Bagryanskaya E.G., Reznikov V.A., Kolosova N.G., Clanton T.L., and Khramtsov V.V. Redox-sensitive mechanism of NO scavenging by nitronyl nitroxides. Free Radic. Biol. Med. 36 (2004) 248-258
33. Murphy M.E., and Sies H. Reversible conversion of nitroxyl anion to nitric oxide by superoxide dismutase. Proc. Natl. Acad. Sci. USA 88 (1991) 10860-10864
34. Hobbs A.J., Fukuto J.M., and Ignarro L.J. Formation of free nitric oxide from l-arginine by nitric oxide synthase-direct enhancement of generation by superoxide dismutase. Proc. Natl. Acad. Sci. USA 91 (1994) 10992-10996
35. Fukuto J.M., Hobbs A.J., and Ignarro L.J. Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems-the role of physiological oxidants and relevance to the biological activity of HNO. Biochem. Biophys. Res. Commun. 196 (1993) 707-713
36. - oxidoreductase and as a dichlorofluorescin peroxidase. J. Biol. Chem. 276 (2001) 35253-35257
37. -): a substrate for superoxide dismutase. Arch. Biochem. Biophys. 402 (2002) 166-171
38. Fukuto J.M., Switzer C.H., Miranda K.M., and Wink D.A. Nitroxyl (HNO): chemistry, biochemistry, and pharmacology. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 335-355
39. Fukuto J.M., Bartberger M.D., Dutton A.S., Paolocci N., Wink D.A., and Houk K.N. The physiological chemistry and biological activity of nitroxyl (HNO): the neglected, misunderstood, and enigmatic nitrogen oxide. Chem. Res. Toxicol. 18 (2005) 790-801
40. Miranda K.M., Paolocci N., Katori T., Thomas D.D., Ford E., Bartberger M.D., Espey M.G., Kass D.A., Feelisch M., Fukuto J.M., and Wink D.A.A. biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc. Natl. Acad. Sci. USA 100 (2003) 9196-9201
41. Wink D.A., and Mitchell J.B. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 25 (1998) 434-456
42. Wink D.A., Hanbauer I., Krishna M.C., Degraff W., Gamson J., and Mitchell J.B. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc. Natl. Acad. Sci. USA 90 (1993) 9813-9817